Johnson & Johnson reports that investigational Ebola vaccine regimen induced durable immune response 1 year after vaccination in Phase 1 study


Johnson & JohnsonJohnson & Johnson announced that final Phase 1 clinical trial data published in JAMA: The Journal of the American Medical Association show that Janssen Pharmaceutical Companies' investigational "prime-boost" Ebola vaccine regimen induced a durable immune response in 100 percent of healthy volunteers one year following vaccination.

Source link